The allogeneic T cell therapies market is poised for substantial growth, anticipated to expand at a compound annual growth rate (CAGR) of 9.75% during the forecast period of 2024-2032. This surge is primarily driven by the rising prevalence of cancer cases globally, coupled with advancements in medical technology and increasing investments in research and development. […]
